Norton Rose Fulbright advises Citic Securities and HSBC on the placing of new shares for a biopharmaceutical company

Global law firm Norton Rose Fulbright has advised Citic Securities and HSBC on the placing of new shares on the Hong Kong Stock Exchange for biopharmaceutical company, Lepu Biopharma Co., Ltd.

Lepu Biopharma has a global vision and focuses on oncology therapeutics. Its mission is to become an innovative leader in providing unmet medical needs of cancer patients through its pioneering research and development.

Citic Securities and HSBC act as the placing agents for the biopharmaceutical company and have agreed to procure the placing of a maximum of 51,170,000 Placing Shares at the Placing Price of HK$4.58 per H share on the Hong Kong Stock Exchange. The net placing proceeds will be used by Lepu Biopharma to further its research and development, clinical trials as well as other workstreams and corporate purposes.

The multi-disciplinary team from Norton Rose Fulbright was led by Head of Hong Kong office and Capital Markets Practice Psyche Tai, as well as Hong-Kong-based partners Doris Ng and Harold Tin and they were supported by senior associate, Timothy Lam. The team advised on all financial and capital market matters through the transaction and placing agreement.